Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Advanced Drainage Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Advanced Drainage Systems Inc trades at $150.47 (market cap $11.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.5× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.53% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WMS | |
|---|---|---|
Market Cap | $39.89B | $11.53B |
Sector | Health | Industrials |
52-Week High | $491.22 | $175.38 |
52-Week Low | $278.09 | $110.89 |
Enterprise Value | $38.15B | $13.10B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Advanced Drainage Systems (WMS) trades at $150.47, up 1.77% today, with a bullish technical signal and strong fundamental profitability. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.07 exceeding the $0.936 estimate. The company maintains robust margins, including a 38.27% gross profit margin and 13.98% net income margin, while cash flow trends indicate solid operational performance despite a net outflow in 2025.
The outlook is positive with a consensus price target of $183.33, suggesting 22% upside, supported by analyst buy ratings. Risks include competitive pressures and a recent Zacks Strong Sell rating, but strong ROE of 24.02% and debt-to-asset improvement to 34.34% in 2025 highlight financial health. Investors should weigh growth potential against market volatility and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
